US NEWS FEEDS
Bethesda-based Northwest Biotherepeutics has raised $12 million as it continues its phase 3 clinical trial for its immunotherapy drug candidate for glioblastoma multiforme brain cancer.
Announced Tuesday, Northwest Bio officials said the funding would be used for general corporate purposes, which could include clinical trial expenses, but did not offer further specifics. The company is developing products to stimulate the immune system to reverse tumor growth and kill cancer cells and has several…
Baltimore Business News - Local Baltimore News | Baltimore Business Journal
READ MORE: Bethesda's Northwest Bio raises $12 million in new funding round